Alzheimer’s disease hurts millions of families worldwide. It slowly steals a loved one’s mind, piece by piece, leaving behind confusion and sadness.
What makes the brain sick?
Inside the brain, a sticky protein called amyloid‑beta (Aβ) can clump together and form plaques. These plaques are thought to damage brain cells and cause memory loss.
New clue: the protein PTP1B
Researchers led by Professor Nicholas Tonks found that a different protein, PTP1B, can be blocked to protect memory. In mouse experiments, stopping PTP1B helped the animals learn and remember better.
PTP1B works together with another protein called SYK. SYK tells brain immune cells, called microglia, to clean up Aβ plaques. When PTP1B is active, microglia get tired and stop working well. Turning off PTP1B wakes them up, letting them clear the harmful plaques.
Why this matters for health
Being overweight or having type‑2 diabetes raises the chance of getting Alzheimer’s. PTP1B is already a target for drugs that treat diabetes and obesity. Linking it to Alzheimer’s opens a door to medicines that could attack both problems.
Hope for better treatments
Most current Alzheimer’s drugs only try to lower Aβ, and many patients see little benefit. Using PTP1B blockers might add another tool—helping the brain clean up plaques while also supporting other therapies.
The Tonks team is now working with a biotech firm to create safe PTP1B inhibitors. The idea is to pair these new drugs with the medicines doctors already use, slowing the disease and giving patients a better life.